Apolipoprotein C-III messenger RNA (APOC3 mRNA) (APOC3 mRNA)

Apolipoprotein C-III (APOC3) messenger RNA (mRNA) is a therapeutic target primarily expressed in hepatocytes, serving as the template for the APOC3 protein which regulates lipid metabolism (NIH Gene ID 345). The APOC3 protein inhibits lipoprotein lipase (LPL) and hepatic lipase, while also preventing the hepatic uptake of triglyceride-rich lipoproteins, thereby increasing circulating triglyceride levels (UniProt P02656). Overexpression or high plasma levels of APOC3 are strongly linked to severe hypertriglyceridemia and an elevated risk of acute pancreatitis and cardiovascular disease (Gaudet et al., 2019, NEJM). Modern pharmacotherapy targets the APOC3 mRNA using antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) to induce its degradation, effectively silencing the production of the protein (Tardif et al., 2022, European Heart Journal). By reducing APOC3 levels, these therapies facilitate the clearance of triglycerides even in the absence of fully functional LPL, providing a critical intervention for conditions like familial chylomicronemia syndrome (FCS) (Esan & Wierzbicki, 2020, Therapy). This target represents a significant advancement in precision medicine for metabolic and cardiovascular health.

Other names

APOC3 transcriptApolipoprotein C3 mRNAApoC-III mRNAApolipoprotein C-III mRNA

Reduction of APOC3 protein synthesis through RNase H-mediated degradation of mRNA by antisense oligonucleotides or RNA-induced silencing complex (RISC) mediated cleavage by small interfering RNAs (siRNAs).